Participating Companies


Aptorum Group [APM] US$455 MM MCap
Ap­to­rum is a phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to de­vel­op­ing and com­mer­cial­iz­ing a broad range of ther­a­peu­tic and di­ag­nos­tic tech­nolo­gies to tack­le un­met med­i­cal needs. Ap­to­rum is pur­su­ing ther­a­peu­tic and di­ag­nos­tic pro­jects in neu­rol­o­gy, in­fec­tious dis­eas­es, gas­troen­terol­o­gy, on­col­o­gy and other dis­ease ar­eas; [more in­for­ma­tion]
Aquestive Therapeutics [AQST] US$144 MM MCap
Aque­s­tive Ther­a­peu­tics is a spe­cial­ty phar­ma­ceu­ti­cal com­pany that ap­plies in­no­va­tive tech­nol­o­gy to solve ther­a­peu­tic problems and im­prove medicines for pa­tients. Aque­s­tive is ad­vanc­ing a late-stage pro­pri­e­tary prod­uct pipe­line to treat CNS con­di­tions and pro­vide al­ter­na­tives to in­va­sive­ly-ad­min­is­tered stan­dard of care ther­a­pies. [more in­for­ma­tion]
Arcus Biosciences [RCUS] US$369 MM MCap
Ar­cus has sev­er­al pro­grams tar­get­ing im­por­tant im­muno-on­col­o­gy path­ways, in­clud­ing a du­al adeno­sine re­cep­tor an­ta­g­on­ist AB928, which is in a Phase 1/1b pro­gram to eval­u­ate AB928 in com­bi­na­tion with other agents in mul­ti­ple tu­mor types, and an an­ti-PD-1 anti­body AB122, which is be­ing eval­u­at­ed in a Phase 1 trial and is be­ing test­ed in com­bi­na­tion with Ar­cus’s other prod­uct can­di­dates. [more in­for­ma­tion]
Aridis Pharmaceuticals Inc. [ARDS] US$46 MM MCap
The use of mAbs rep­re­sents an in­no­va­tive treat­ment ap­proach that har­ness­es the hu­man im­mune sys­tem to fight in­fec­tions and is de­signed to over­come the de­fi­cien­cies as­so­ci­at­ed with the cur­rent stan­dard of care, broad spec­trum antibi­otics. [more in­for­ma­tion]
Arvinas [ARVN] US$868 MM MCap
Arv­i­nas us­es its pro­pri­e­tary tech­nol­o­gy plat­form to en­gi­neer pro­te­ol­y­sis tar­get­ing chimeras, or PRO­TAC™ tar­get­ed pro­tein de­graders, that are de­signed to har­ness the body’s own na­t­u­ral pro­tein dis­pos­al sys­tem to se­lec­tive­ly and ef­fi­cient­ly de­grade and re­move dis­ease-caus­ing pro­teins. [more in­for­ma­tion]
ASLAN Pharmaceuticals [ASLN] US$16 MM MCap
AS­LAN Phar­ma­ceu­ti­cals (Nas­daq:ASLN, TPEx:6497) is a clin­i­cal-stage on­col­o­gy-fo­cused bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing nov­el ther­a­peu­tics for glob­al mar­kets. Led by a se­nior ma­n­age­ment team with ex­ten­sive ex­pe­ri­ence in glob­al and re­gio­n­al de­vel­op­ment and com­mer­cial­i­sa­tion, AS­LAN is head­quar­tered in Sin­ga­pore and has of­fices in Tai­wan and Chi­na. [more in­for­ma­tion]
BioXcel Therapeutics, Inc. [BTAI] US$70 MM MCap
Our two most ad­vanced clin­i­cal de­vel­op­ment pro­grams are BX­CL501, a sublin­gual thin film for­mu­la­tion of dexmede­to­mi­dine de­signed for acute treat­ment of ag­i­ta­tion re­sult­ing from neu­ro­log­i­cal and psychi­a­tric di­s­or­ders, and BX­CL701, an im­muno-on­col­o­gy agent de­signed for treat­ment of a rare form of pros­tate can­cer and for treat­ment of pan­cre­at­ic can­cer. [more in­for­ma­tion]
Constellation Pharmaceuticals [CNST] US$835 MM MCap
Con­stel­la­tion is driv­ing de­vel­op­ment of the EZH2 in­hibi­tors CPI-1205 and CPI-0209 for the treat­ment of me­tastat­ic cas­tra­tion-re­sis­tant pros­tate can­cer and other can­cers as well as the BET in­hibi­tor CPI-0610 for the treat­ment of myelo­fi­bro­sis. [more in­for­ma­tion]
DiaMedica Inc. [DMAC] US$36 MM MCap
Two forms of DM199 iso­lat­ed from urine and pig pan­creas are ap­proved in Ja­pan and Chi­na where mil­lions of pa­tients have been treat­ed. Di­aMed­i­ca's largest share­hold­er is Fo­s­un Phar­ma/Hermed Cap­i­tal and Fo­s­un Phar­ma li­censed DM199 for use in Chi­na in 2nd half of 2018. [more in­for­ma­tion]
Eidos Therapeutics [EIDX] US$1,623 MM MCap
Ei­dos Ther­a­peu­tics is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on ad­dress­ing the large and grow­ing un­met need in dis­eas­es caused by tran­sthyretin, or TTR, amy­loi­do­sis, or AT­TR. [more in­for­ma­tion]
Entasis Therapeutics [ETTX] US$73 MM MCap
In March 2016, we raised an ad­di­tio­n­al $50 mil­lion in a Se­ries B fi­nanc­ing from a strong syn­di­cate of in­ves­tors, in­clud­ing Clarus, Frazi­er Health­care Part­n­ers, No­vo A/S and Even­tide Funds, to ad­vance our pipe­line of break­through an­ti-in­fec­tive prod­ucts. [more in­for­ma­tion]
Equillium Inc [EQ] US$57 MM MCap
Equil­li­um be­lieves that EQ001 has the po­ten­tial to be a best-in-class dis­ease mod­i­fy­ing ther­a­peu­tic and is ad­vanc­ing EQ001 in­to clin­i­cal de­vel­op­ment in mul­ti­ple im­muno-in­flam­ma­to­ry in­di­ca­tions with high un­met med­i­cal need. [more in­for­ma­tion]
Evofem Biosciences, Inc. [EVFM] US$251 MM MCap
Se­cured $30M strate­g­ic in­vest­ment from PDL Bio­S­ciences (PDLI) in April 2019 for 6.7M shares at $4.50 (26% pre­mi­um to pri­or day close) and 25% war­rant cov­er­age. [more in­for­ma­tion]
Gamida Cell Ltd [GMDA] US$127 MM MCap
Gami­da Cell is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany com­mitt­ed to de­vel­op­ing nov­el cell ther­a­pies with the po­ten­tial to cure dif­fi­cult-to-treat can­cers and rare, se­ri­ous he­ma­to­log­ic dis­eas­es. We are lev­er­ag­ing our pro­pri­e­tary ni­coti­namide-based cell ex­pan­sion tech­nol­o­gy, or NAM tech­nol­o­gy, to de­vel­op prod­uct can­di­dates de­signed to ad­dress the lim­i­ta­tions of cell ther­a­pies. [more in­for­ma­tion]
Hua Medicine [2552:HK]
Hua Medicine is a clin­i­cal stage drug de­vel­op­ment com­pany cur­rent­ly fo­cused on de­vel­op­ing a glob­al first-in-class oral drug, Dorza­gli­atin or HM­S5552, for the treat­ment of Type 2 Di­a­betes (T2D). Dorza­gli­atin is a fourth gen­er­a­tion glu­cok­i­nase ac­ti­va­tor, orig­i­nat­ed at Roche AG, and in-li­censed by Hua Medicine as a pre-clin­i­cal stage com­pound. [more in­for­ma­tion]
Menlo Therapeutics Inc. [MNLO] US$115 MM MCap
The com­pany’s clin­i­cal de­vel­op­ment pro­gram for ser­lo­p­i­tant in­cludes two on­go­ing Phase 3 clin­i­cal trials for the treat­ment of pru­ri­tus as­so­ci­at­ed with pruri­go no­du­laris, a planned Phase 3 pro­gram for the treat­ment of pru­ri­tus as­so­ci­at­ed with pso­ri­a­sis, and an on­go­ing Phase 2 clin­i­cal trial for the treat­ment of chron­ic pru­ri­tus of un­known ori­gin. [more in­for­ma­tion]
Millendo Therapeutics [MLND] US$104 MM MCap
Mil­len­do Ther­a­peu­tics is a late-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on de­vel­op­ing nov­el treat­ments for or­phan en­docrine dis­eas­es where cur­rent ther­a­pies do not ex­ist or are in­suf­fi­cient. As a lead­ing or­phan en­docrine com­pany, Mil­len­do cre­ates dist­inct and trans­for­ma­tive treat­ments where there is a sig­ni­f­i­cant un­met med­i­cal need. [more in­for­ma­tion]
MorphoSys AG [MOR] US$3,316 MM MCap
Based on its lead­ing ex­per­tise in anti­body, pro­tein and pep­tide tech­nolo­gies, Mor­phoSys, to­gether with its part­n­ers, has de­vel­oped and con­tribut­ed to the de­vel­op­ment of more than 100 prod­uct can­di­dates, of which 29 are cur­rent­ly in clin­i­cal de­vel­op­ment. [more in­for­ma­tion]
Nanobiotix SA [NANO:PA] €163 MM MCap
Nano­bi­otix is a lead­ing, clin­i­cal-stage nanomedicine com­pany pi­oneer­ing new ap­proach­es to sig­ni­f­i­cant­ly change pa­tient out­comes by bring­ing nano­physics to the heart of the cell. Nano­bi­otix’s Im­muno-On­col­o­gy pro­gram has the po­ten­tial to bring a new di­men­sion to can­cer im­munother­a­pies. [more in­for­ma­tion]
Scholar Rock [SRRK] US$266 MM MCap
Our lead prod­uct can­di­date, SRK-015, a high­ly se­lec­tive in­hibi­tor of the ac­ti­va­tion of the growth fac­tor myo­s­tatin in skele­tal mus­cle, is cur­rent­ly in de­vel­op­ment for the treat­ment of spi­nal mus­cu­lar at­ro­phy, or SMA. [more in­for­ma­tion]
Sol-Gel Technologies Ltd. [SLGL] US$185 MM MCap
Com­mer­cial­iz­ing brand­ed gener­ic top­i­cal drug prod­ucts (skin dis­eas­es). 2 P3 read­outs in 2019: Rosacea: mid-2019; Acne: YE [more in­for­ma­tion]
Solebury Trout
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]
Surface Oncology [SURF] US$45 MM MCap
Sur­face On­col­o­gy is de­vel­op­ing next-gen­er­a­tion anti­body ther­a­pies fo­cused on the tu­mor mi­croen­vi­ron­ment with lead pro­grams tar­get­ing CD73, CD39, IL-27 and CD47. Our di­verse clin­i­cal and pre­clin­i­cal pipe­line of im­mune-en­hanc­ing anti­body can­di­dates tar­get the in­nate and adap­tive arms of the im­mune sys­tem to de­liv­er dra­mat­i­cal­ly dif­fer­ent ther­a­pies for pa­tients and their fam­i­lies. [more in­for­ma­tion]
Taiwan Liposome Company [TLC] US$185 MM MCap
TLC is a clin­i­cal-stage spe­cial­ty phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to the de­vel­op­ment and com­mer­cial­iza­tion of nov­el nanomedicines that com­bine pro­pri­e­tary lipid-as­sem­bled drug de­liv­ery plat­forms with ap­proved ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (APIs). All pro­grams ex­pect­ed to be in late or piv­o­tal stage by the end of 2020. [more in­for­ma­tion]
TCR2 Therapeutics [TCRR] US$357 MM MCap
is a clin­i­cal-stage im­munother­a­py com­pany de­vel­op­ing the next gen­er­a­tion of nov­el T cell ther­a­pies for pa­tients suf­fer­ing from can­cer. TCR2's pro­pri­e­tary T cell re­cep­tor (TCR) Fu­sion Con­struct T cells (TRuC-T™ cells) spe­cif­i­cal­ly rec­og­nize and kill can­cer cells by har­ness­ing sig­nal­ing from the en­tire TCR, in­de­pen­dent of hu­man leuko­cyte anti­gens (HLA). [more in­for­ma­tion]
Unum Therapeutics Inc. [UMRX] US$34 MM MCap
Four prod­uct can­di­dates cur­rent­ly in Phase I test­ing are based up­on its nov­el Anti­body-Cou­pled T cell Re­cep­tor (AC­TR) ther­a­py, a uni­ver­sal T cell that can be tar­get­ed us­ing tu­mor-spe­cif­ic anti­bodies to at­tack dif­fer­ent tu­mor types. [more in­for­ma­tion]
Vaccinex, Inc. [VCNX] US$72 MM MCap
Its lead prod­uct, pepinemab, is an anti­body against semaphorin 4D, a nov­el im­munother­a­py tar­get to mo­d­u­late im­mune re­sponse to solid tu­mors and chron­ic in­flam­ma­tion that drives neu­rode­gen­er­a­tive dis­eas­es. [more in­for­ma­tion]